8-K

                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549






                                    FORM 8-K

                                 CURRENT REPORT

                         Pursuant to Section 13 or 15(d)
                     Of the Securities Exchange Act of 1934





Date of Report (Date of earliest event reported):  March 16, 2004


                           INTERLEUKIN GENETICS, INC.
                           --------------------------
             (Exact name of registrant as specified in its charter)


Delaware                      000-23413                94-3123681
- --------                      ---------                ----------
(State or other               (Commission              (IRS Employer
jurisdiction of               File Number)             Identification No.)
incorporation)


135 Beaver Street, Waltham, MA  02452
- -------------------------------------
(Address of principal executive offices)



Registrant's telephone number, including area code:  (781) 398-0700
                                                     --------------




Item 5.   Other Events.
- -------   -------------

     On March 16, 2004, Interleukin Genetics, Inc. publicly disseminated a press
     release announcing that it had achieved a pre-defined milestone in its
     Nutrigenomics Collaboration with Alticor and as a result of this
     achievement had received a $2,000,000 capital contribution from Alticor.

     The information contained in the press release is incorporated herein by
     reference and filed as Exhibit 99.1 hereto


Item 7.   Financial Statements and Exhibits.
- -------   ----------------------------------

(c)       Exhibit

 99.1     Press Release dated March 16, 2004



                                   SIGNATURES

  Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                        INTERLEUKIN GENETICS, INC.
                                        --------------------------
                                        (Registrant)


Date:  March 16, 2004                   /s/ Fenel M. Eloi
                                         ------------------------------------
                                         Fenel M. Eloi, Chief Operating Officer,
                                         Chief Financial Officer, Treasurer and
                                         Secretary and Treasurer

EX-99.1

                                                                    Exhibit 99.1

   Interleukin Achieves Milestone in Nutrigenomics Collaboration with Alticor

    WALTHAM, Mass.--(BUSINESS WIRE)--March 16, 2004--Interleukin
Genetics, Inc. (OTCBB: ILGN) reported today that it has signed a
Distribution Agreement with Access Business Group International LLC, a
subsidiary of Alticor Inc., for DNA-based risk assessment tests.
    With the execution of this agreement, Interleukin has achieved the
"Milestone" under the Stock Purchase Agreement, dated March 5, 2003,
between Interleukin and Alticor. The Milestone is met when Interleukin
enters into a genetic testing agreement with one or more customers of
such size that the projected internal rate of return with respect to
the project is at least 20% with a payback period of three years or
less.
    As a result of the achievement of this Milestone, Alticor has made
an additional $2,000,000 capital contribution to Interleukin with no
additional shares being issued to Alticor.
    "We are extremely pleased to have met this milestone in our
alliance with Alticor," said Philip R. Reilly, MD, JD, Interleukin's
Chief Executive Officer. "This is an important event for the company
as we execute our portion of the collaborative agreement and prepare
for product launch next year."

    About Interleukin Genetics

    Interleukin Genetics is a biotechnology company focused on
inflammation. The company uses functional genomics to help in the
development of risk assessment, nutritional and therapeutic products
based on the genetic variations in people to help prevent, ameliorate
or treat diseases involving inflammation. Interleukin's current
programs focus on cardiovascular disease, osteoporosis, rheumatoid
arthritis and Alzheimer's disease. Interleukin expects that these
programs will produce products that will personalize the selection of
nutritional and therapeutic products and enable the managed care
industry to improve patient care and better allocate resources. For
more information about Interleukin and its ongoing programs, please
visit http://www.ilgenetics.com.

    Certain statements contained herein are "forward-looking"
statements including statements regarding our ability to develop
diagnostic, personalized nutritional and therapeutic products to
prevent or treat diseases of inflammation and to enable the managed
care industry to improve patient care and better allocate resources.
Because such statements include risks and uncertainties, actual
results may differ materially from those expressed or implied by such
forward-looking statements. Factors that could cause actual results to
differ materially from those expressed or implied by such
forward-looking statements include, but are not limited to, our
ability to develop diagnostic, personalized nutritional and
therapeutic products to prevent or treat diseases of inflammation and
to enable the managed care industry to improve patient care and better
allocate resources and our ability to market such products, our
ability to complete clinical research and data analysis, meeting our
clinical studies' endpoints, risk of market acceptance of our
products, risk of technology and products obsolescence, delays in
development of products, reliance on partners, competitive risks and
those risks and uncertainties described in our Form 10-Q for the three
months ended September 30, 2003, as filed on November 12, 2003, and in
other filings made by us with the Securities and Exchange Commission.
We disclaim any obligation or intention to update these
forward-looking statements.

    CONTACT: Interleukin Genetics, Inc.
             Fenel M. Eloi, 781-398-0700